TESTING
45. Orsted DD, Nordestgaard BG, Jensen GB, Schnohr P, Bojesen SE. Prostate-specific antigen and long-term prediction of prostate cancer incidence and mortality in the general population. Eur Urol 2012;61(5):865-874.
61. Ishidoya S, Ito A, Orikasa K et al. The outcome of prostate cancer screening in a normal Japanese population with PSA of 2-4 ng/ml and the free/total PSA under 12%. Jpn J Clin Oncol 2008;38(12):844-848.
46. Vickers AJ, Ulmert D, Sjoberg DD et al. Strategy for detection of prostate cancer based on relation between prostate specific antigen at age 40-55 and long term risk of metastasis: case-control study. BMJ 2013;346:f2023.
62. Rowe EW, Laniado ME, Walker MM, Patel A. Prostate cancer detection in men with a ‘normal’ total prostate-specific antigen (PSA) level using percentage free PSA: a prospective screening study. BJU Int 2005;95(9):1249-1252.
47. Australian Institute of Health and Welfare. Australian Cancer Incidence and Mortality (ACIM) books [web page]. Last updated 13/02/2014; Available from: http://www.aihw.gov.au/ acim-books.
63. Uzzo RG, Pinover WH, Horwitz EM et al. Free prostatespecific antigen improves prostate cancer detection in a highrisk population of men with a normal total PSA and digital rectal examination. Urology 2003;61(4):754-759.
48. The Royal College of Pathologists of Australasia. Prostate specific antigen testing: Age-related interpretation in early prostate cancer detection. Revised position statement. Document number D135107. EACP. 2011
64. Makinen T, Tammela TL, Hakama M et al. Prostate cancer screening within a prostate specific antigen range of 3 to 3.9 ng./ml.: a comparison of digital rectal examination and free prostate specific antigen as supplemental screening tests. J Urol 2001;166(4):1339-1342.
49. Carvalhal GF, Smith DS, Mager DE, Ramos C, Catalona WJ. Digital rectal examination for detecting prostate cancer at prostate specific antigen levels of 4 ng./ml. or less. J Urol 1999;161(3):835-839.
65. Bokhorst LP, Zhu X, Bul M, Bangma CH, Schroder FH, Roobol MJ. Positive predictive value of prostate biopsy indicated by prostate-specific-antigen-based prostate cancer screening: trends over time in a European randomized trial. BJU Int 2012;110(11):1654-1660.
50. Fowler JE JR, Bigler SA, Farabaugh PB, Wilson SS. Prostate cancer detection in Black and White men with abnormal digital rectal examination and prostate specific antigen less than 4 ng./ml. J Urol 2000;164(6):1961-1963.
66. Hugosson J, Aus G, Bergdahl S et al. Population-based screening for prostate cancer by measuring free and total serum prostate-specific antigen in Sweden. BJU Int 2003;92 Suppl 2:39-43.
51. Galic J, Karner I, Cenan L et al. Comparison of digital rectal examination and prostate specific antigen in early detection of prostate cancer. Coll Antropol 2003;27:Suppl-6.
67. Catalona WJ, Partin AW, Finlay JA et al. Use of percentage of free prostate-specific antigen to identify men at high risk of prostate cancer when PSA levels are 2.51 to 4 ng/mL and digital rectal examination is not suspicious for prostate cancer: an alternative model. Urology 1999;54(2):220-224.
52. Gomez-Guerra LS, Martinez-Fierro ML, Alcantara-Aragon V et al. Population based prostate cancer screening in north Mexico reveals a high prevalence of aggressive tumors in detected cases. BMC Cancer 2009;9:91.
68 Egawa S, Suyama K, Matsumoto K, Kuwao S, Baba S. Prospective evaluation of prostate cancer detection by prostate specific antigen related parameters: comparison in serum and plasma samples. J Urol 2002;167(1):97-102.
53. Thompson IM, Tangen CM, Goodman PJ et al. Finasteride improves the sensitivity of digital rectal examination for prostate cancer detection. J Urol 2007;177(5):1749-1752. 54. Royal Australian College of General Practitioners. Guidelines for preventative activities in general practice. East Melbourne: RACGP; 2012.
69. Kobayashi T, Kawahara T, Nishizawa K, Ogura K, Mitsumori K, Ide Y. Volume-adjusted prostate-specific antigen (PSA) variables in detecting impalpable prostate cancer in men with PSA levels of 2-4 ng/mL: transabdominal measurement makes a significant contribution. BJU International 2005;95(9):1245-1248.
55. Grenabo Bergdahl A, Holmberg E, Moss S, Hugosson J. Incidence of prostate cancer after termination of screening in a population-based randomised screening trial. Eur Urol 2013;64(5):703-709.
70. Lodding P, Aus G, Bergdahl S et al. Characteristics of screening detected prostate cancer in men 50 to 66 years old with 3 to 4 ng./ml. Prostate specific antigen. J Urol 1998;159(3):899-903.
56. Commonwealth of Australia. Australian Life Tables 2010-2012. Last updated 2014; Available from: http://www.aga.gov.au/ publications/life_table_2010-12/default.asp.
71. Okihara K, Fritsche HA, Ayala A, Johnston DA, Allard WJ, Babaian RJ. Can complexed prostate specific antigen and prostatic volume enhance prostate cancer detection in men with total prostate specific antigen between 2.5 And 4.0 Ng./ Ml. J Urol 2001;165:1930-1936.
57. Nordstrom T, Aly M, Eklund M, Egevad L, Gronberg H. A genetic score can identify men at high risk for prostate cancer among men with prostate-specific antigen of 1-3 ng/ml. Eur Urol 2014;65(6):1184-1190. 58. Finne P, Auvinen A, Maattanen L et al. Diagnostic value of free prostate-specific antigen among men with a prostate-specific antigen level of <3.0 microg per liter. Eur Urol 2008;54(2):362370.
72. Raaijmakers R, Blijenberg BG, Finlay JA et al. Prostate cancer detection in the prostate specific antigen range of 2.0 to 3.9 ng/ml: value of percent free prostate specific antigen on tumor detection and tumor aggressiveness. J Urol 2004;171:22452249.
59. Carter HB, Pearson JD. PSA velocity for the diagnosis of early prostate cancer. A new concept. Urol Clin North Am 1993;20(4):665-670.
73. Reissigl A, Klocker H, Pointner J et al. Usefulness of the ratio free/total prostate-specific antigen in addition to total PSA levels in prostate cancer screening. Urology 1996;48(6A):6266.
60. Arlen PM, Bianco F, Dahut WL et al. Prostate Specific Antigen Working Group guidelines on prostate specific antigen doubling time. J Urol 2008;179(6):2181-2185.
63